Corvallis Hospital participates in a national sepsis study
A treatment Good Samaritan Regional Medical Center helped develop in the fight against COVID-19 will soon take on a new purpose. In the coming months, the treatment will be used in a nationwide study of septic shock, a life-threatening reaction to infection.
The PURIFY‑RCT study will investigate the use of the Seraph 100 Microbind Affinity Blood Filter as a blood purification treatment for critically ill patients in septic shock. The study is funded by the Department of Defense and sponsored by the University of the Uniformed Services, the Henry M. Jackson Foundation for the Advancement of Military Medicine and ExThera Medical Corp., the manufacturer of the filter.
For more than a year, critical care specialist Brian Delmonaco, MD, and his critical care team have found success using this blood filter on some of the sickest COVID-19 patients. Now, USI staff will use their expertise in the study, which can last up to two years.
“A study like PURIFY-RCT allows our critical care team to network with larger research centers,” said Dr. Delmonaco.
The Seraph 100 filter received Emergency Use Authorization from the United States Food and Drug Administration in April 2020 to treat critically ill COVID-19 patients.
Participants involved in the study will be intensive care patients who have septic shock, bacteria in their blood and are taking certain medications to raise abnormally low blood pressure.
Good Samaritan, the only participant in the Pacific Northwest, has prestigious medical partners in the study, including Baylor Scott & White Health, University of Texas Southwestern Medical Center and University of Southern California.
“The Good Samaritan Regional Medical Center is a small but powerful clinical site for the PURIFY-RCT study. The caliber of other clinical sites in terms of academic excellence brings us closer to a highly esteemed company,” said Dr. Delmonaco.
The research, which will enroll 60 patients, will compare in a 2-to-1 ratio a larger group receiving Seraph filter treatment for up to four days and a smaller group receiving normal ICU care.
“It is an honor to be part of the PURIFY-RCT study and to feature our hospital among the top health research institutions in the country,” said Dr. Delmonaco.